Insulin Pump Systems
Wearable insulin delivery and automated insulin delivery systems.
Market snapshot
These figures describe Diabetes & Metabolic Devices (4.8.3), the segment that Insulin Pump Systems sits within — not Insulin Pump Systems on its own.
Within electromedical and instrument manufacturing (NAICS 334510/339112); the Census Bureau does not split out diabetes devices, so the segment is not separately sized.
Business model & economics
Revenue model
Devices plus high-margin recurring sensors and supplies
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- High
recurring CGM sensors and pump supplies
recurring-consumable economics
Characteristics
- Among the fastest-growing medtech categories.
- CGM adoption expanding into type 2 and wellness.
- Recurring sensor-and-supply razor-and-blade model.
Geographic concentration
Diabetes and metabolic-device manufacturing clusters in the major medtech hubs — Minnesota, Massachusetts, Utah, and California — home to the sector's leading device makers.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 334510/339112. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- Diabetes-device strategics
- Diversified medtech platforms
- VC-backed innovators
What’s driving deals
- CGM and automated-insulin-delivery growth.
- Expansion into type 2 and metabolic wellness.
- Recurring-consumable economics.
Find Insulin Pump Systems acquisition targets
Search Acquisera’s index for companies classified under Insulin Pump Systems (4.8.3.4) and build a targeted deal pipeline.
Search companies